SCHEMBL243150

SCHEMBL243150

BrCc1ccc2nonc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 4/20 0.53
KCNH2 Q12809 4/20 0.53
ENPP2 Q13822 2/20 0.48
ALDH1A1 P00352 4/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PKM P14618 1/20 0.47
NR3C1 P04150 1/20 0.39
PGR P06401 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
TOP2A P11388 1/20 0.36
THRB P10828 1/20 0.34
GRIA3 P42263 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8567072 0.83 KCNJ1 (0.59) KCNJ1KCNH2ENPP2ALDH1A1ALOX15
SCHEMBL2093216 0.78 KCNJ1 (0.53) KCNJ1KCNH2ENPP2ALDH1A1ALOX15
SCHEMBL13610285 0.78 KCNJ1 (0.53) KCNJ1KCNH2ENPP2ALDH1A1ALOX15
SCHEMBL16373414 0.78 KCNJ1 (0.53) KCNJ1KCNH2ENPP2ALDH1A1ALOX15
SCHEMBL2056122 0.78 KCNJ1 (0.53) KCNJ1KCNH2ENPP2ALDH1A1ALOX15
SCHEMBL8256316 0.78 KCNJ1 (0.53) KCNJ1KCNH2ENPP2ALDH1A1ALOX15
SCHEMBL8913108 0.78 ENPP2 (0.54) KCNJ1KCNH2ENPP2ALDH1A1ALOX15
SCHEMBL3271828 0.78 KCNJ1 (0.53) KCNJ1KCNH2ENPP2ALDH1A1ALOX15
Hydrochloric Acid SCHEMBL19119426 0.77 PKM (0.54) KCNJ1KCNH2ENPP2ALDH1A1ALOX15
SCHEMBL2731118 0.75 KCNJ1 (0.50) KCNJ1KCNH2ENPP2ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 US disclosed
CN-114591226-B Preparation method of nicotinaldehyde derivative 南京益恩生物科技有限公司 2024-09-17 CN disclosed
CN-116730940-B Heterocyclic substituted biphenyl compound and medical application thereof 中国药科大学 2024-08-30 CN disclosed
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2024-08-29 US disclosed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117986158-A Substituted biphenyl compound, preparation method and application 云南大学 2024-05-07 CN disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
EP-4347590-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 EP disclosed
CN-116730940-A Heterocyclic substituted biphenyl compound and medical application thereof 中国药科大学 2023-09-12 CN disclosed
US-11725000-B2 Apoptosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-08-15 US disclosed
EP-0640595-B1 SUBSTITUTED TERTIARY AMINO COMPOUND OR SALT THEREOF YAMANOUCHI PHARMA CO LTD (JP) 1999-03-24 EP disclosed
WO-1999000669-A1 NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION ISIS PHARMACEUTICALS, INC. (US) 1999-01-07 WO disclosed
EP-0863898-A1 ENDOTHELIN RECEPTOR ANTAGONISTS MERCK PATENT GmbH (DE) 1998-09-16 EP disclosed
US-5808139-A CONTROLLING COMPLEXING WITH CYMOPOLY COMPOUNDS LIGAND PHARMACEUTICALS INCORPORATED (US) 1998-09-15 US disclosed
US-5674886-A AROMATASE INHIBITOR; BREAST CANCER; UROGENITAL DISORDERS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1997-10-07 US disclosed
WO-1997019077-A1 ENDOTHELIN RECEPTOR ANTAGONISTS MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1997-05-29 WO disclosed
US-5538976-A ANTICARCINOGENIC AGENTS AND ENZYME INHIBITORS FOR AROMATASE YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1996-07-23 US disclosed
EP-0641785-A1 TRIAZOLYLATED TERTIARY AMINE COMPOUND OR SALT THEREOF YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1995-03-08 EP disclosed
EP-0640595-A1 NOVEL SUBSTITUTED TERTIARY AMINO COMPOUND OR SALT THEREOF YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1995-03-01 EP disclosed
WO-1994024080-A1 PROGESTERONE RECEPTOR AGONIST AND ANTAGONISTS LIGAND PHARMACEUTICALS INC. (US) 1994-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11725000-B2 Apoptosis inhibitors BAX, SDHA, SDHB KCNJ1 3934/4885KCNH2 3722/4885ENPP2 3156/4885
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 KCNJ1 4552/4885KCNH2 4443/4885ENPP2 2197/4885
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS PNPO, PDXK, PLPBP KCNJ1 1539/4885KCNH2 1919/4885ENPP2 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.